Strive Q3 2026 earnings
Net income of $509.0 million driven by a $533.7 million unrealized gain on digital assets.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $2.70B | +106.5% | -8.3% | Ex. 99.1, income statement |
| EPS (GAAP) | $5.24 | +235.5% | +139.0% | Ex. 99.1, income statement |
| EPS (adjusted) | $5.46 | +271.4% | +49.6% | Ex. 99.1, income statement |
| Net income | $509.0M | +4,860.0% | +197.4% | Ex. 99.1, income statement |
| Adj. EBITDA | $513.5M | +4,860.0% | +197.4% | Ex. 99.1, income statement |
| Adj. EBITDA margin | 19.0% | +19.0 pp | +2.1 pp | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Investment advisory fees | $1.56B | +21.5% | 57.9% | — |
| Medical device revenues | $1.13B | — | 42.1% | — |
| Other revenue | $4M | -20.0% | 0.1% | — |
Margins and costs
- Gross margin 19.0% (prior 16.9%, change +2.1 pp)
- Operating expenses $38.70B (+24.6% YoY)
- One-offs in the quarter Impairment of medical device research and development intangible asset: $14.65M; Goodwill and intangible asset impairment: $140.79M
- Effective tax rate 0.0% (prior-year 0.0%, year-to-date 0.0%)
- Non-GAAP bridge Adds back share-based compensation ($6.52M), impairment ($14.65M), goodwill ($140.79M), transaction costs ($6.53M), and bargain purchase gain ($66.70M) to GAAP net income.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Bitcoin Yield | 23.9% | 23.9% | 37.7% | -13.8 pp |
| Cash and cash equivalents | $490.4M | $154.9M | $0 | +217.0% |
| Digital assets, at fair value | $2.34B | $2.34B | $0 | 0.0% |
Guidance
not stated in the 8-K
What drove it
- Revenue story Investment advisory fees grew 21.5% YoY to $1.56B; medical device revenues grew 21.5% YoY to $1.13B; other revenue declined 20.0% YoY to $4M.
- EPS story EPS growth driven by a $533.7 million unrealized gain on digital assets and a $8.8 million gain on investments in preferred equity.
- One-off check Impairment of medical device R&D intangible asset ($14.65M) and goodwill and intangible asset impairment ($140.79M).
The good
- Net income of $509.0 million driven by a $533.7 million unrealized gain on digital assets.
- Adjusted EBITDA margin expanded to 19.0% (+2.1 pp YoY).
The bad
- Medical device R&D intangible asset impairment of $14.65M.
- Goodwill and intangible asset impairment of $140.79M.
The ugly
- none
Open questions
- The release references a 'Bitcoin accumulation results' section but does not provide the specific Bitcoin yield percentage for Q3.
- The release mentions evaluating opportunities to leverage its balance sheet (banking, brokerage, etc.) but does not disclose any specific commitments or capital allocation.
Full release
Strive (ASST) earnings release, November 6, 2026
1
Strive, Inc. Announces
Third
Quarter 2026 Financial Results
DALLAS, TX — (GLOBE NEWSWIRE) — November 6, 2026
- Strive, Inc. (Nasdaq: ASST; SATA; SATS) (“Strive” or the
“Company”) today announced its financial results for the third quarter ended
September 30, 2026.
Key
Highlights:
▪ Acquired a total of
8,136 bitcoin during the third quarter ended
September 30, 2026 and
20,373 bitcoin during the nine months ended September 30, 2026.
▪ Acquired an additional
15,124 bitcoin during the period from
October 1, 2026 through
October 30, 2026.
▪ Achieved the following Bitcoin accumulation results:
▪ As of
October 30, 2026, Strive's cash and cash equivalents totaled
$490.4 million and our position in Variable Rate Series
A Perpetual Preferred Stock of Strategy Inc. ("STRC Stock") had a fair value of
$50.1 million. Strive had
118,117,620 and
9,213,489 shares of Class A common stock and Class B common stock, respectively, and
14,030,176 and
7,003,418 shares of Variable Rate Series A Perpetual Preferred Stock ("SATA Stock") and
15.00% Series A Perpetual SATS
Preferred Stock ("
SATS Stock"), respectively, outstanding as of
October 30, 2026.
▪ On October 20, 2026, completed a registered public offering of 7,000,000 shares of its SATS Stock, for net proceeds of approximately $609.0 million, after deducting the underwriting discounts and commissions. The SATS Stock is listed for trading on the Nasdaq Global Market under the symbol “SATS.”
▪ GAAP net income of
$509.0 million for the three months ended September 30, 2026. Net income per common share for the same period was
$5.24 on a fully diluted basis.
▪ Non-GAAP adjusted net income attributable to common stockholders¹ of
$494.6 million, or
$5.46 per diluted common share¹, for the three months ended September 30, 2026. Non-GAAP adjusted net income attributable to common stockholders subtracts non-recurring and non-cash items from GAAP net loss attributable to common stockholders.
▪ As part of its overall investment strategy, the Company is evaluating various opportunities to leverage its balance sheet, including banking, brokerage, decentralized finance, reinsurance, structured ABS, and tokenization, among other opportunities, taking into account underwriting conditions, tax implications, regulatory considerations, alignment with its broader investment objectives, and other relevant factors.
"Strive has continued to successfully execute on its treasury management strategy, delivering a strong bitcoin yield year to date in
2026, which I believe is the primary driver of our common equity's outperformance relative to Bitcoin so far this year," said
Matthew Cole, Chairman & Chief Executive Officer of Strive, Inc. "With the recent issuance of SATS, we believe Strive has never been in a better position to generate long-term returns in excess of Bitcoin for our common equity shareholders."²
STRIVE, INC.
CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
(in thousands, except share and per share data)³
Financial statements
Income Statement
(unaudited)
| Successor – Three Months Ended September 30, 2026 | Successor – Period From September 12, 2025 to September 30, 2025 | Predecessor – Period From July 1, 2025 to September 11, 2025 | |
|---|---|---|---|
| Revenues: | |||
| Investment advisory fees | 1,559 | 246 | 1,283 |
| Medical device revenues | 1,133 | ||
| Other revenue | 4 | 9 | 5 |
| Total revenues | 2,696 | 255 | 1,288 |
| Operating expenses: | |||
| Fund management and administration | 1,583 | 282 | 1,251 |
| Employee compensation and benefits | 15,633 | 18,720 | 3,151 |
| General and administrative expense | 6,669 | 445 | 871 |
| Impairment of medical device research and development intangible asset | 14,650 | ||
| Marketing and advertising | 86 | 18 | 68 |
| Depreciation and amortization | 78 | 12 | 43 |
| Total operating expenses | 38,699 | 19,477 | 5,384 |
| Investment gains (losses): | |||
| Net unrealized gain (loss) on digital assets, at fair value | 533,697 | -10,133 | |
| Net unrealized gain on investments in preferred equity, at fair value | 8,833 | ||
| Other investment gain | 1,497 | ||
| Other derivative loss | -14,731 | ||
| Total investment gains (losses) | 544,027 | -24,864 | |
| Net operating income (loss) | 508,024 | -44,086 | -4,096 |
| Other income (expense): | |||
| Other income | 1,008 | 68 | 10 |
| Goodwill and intangible asset impairment | -140,785 | ||
| Transaction costs | -7,484 | -10,280 | |
| Total other income (expense) | 1,008 | -148,201 | -10,270 |
| Net income (loss) before income taxes | 509,032 | -192,287 | -14,366 |
| Net income (loss) | 509,032 | -192,287 | -14,366 |
| Dividends on preferred stock | -34,231 | ||
| Net income (loss) attributable to common stockholders | 474,801 | -192,287 | -14,366 |
| Weighted average number of common shares outstanding: | |||
| Basic (1) | 89,080,303 | 43,617,459 | 2,325,783 |
| Diluted (1) | 90,534,798 | 43,617,459 | 2,325,783 |
| Net income (loss) per common share: | |||
| Basic (1) | 5.33 | -4.41 | -6.18 |
| Diluted (1) | 5.24 | -4.41 | -6.18 |
Income Statement
(in thousands, except share and per share data)
| Successor – Nine Months Ended September 30, 2026 – (unaudited) | Successor – Period From September 12, 2025 to September 30, 2025 – (unaudited) | Predecessor – Period From January 1, 2025 to September 11, 2025 – (audited) | |
|---|---|---|---|
| Revenues: | |||
| Investment advisory fees | 4,418 | 246 | 4,187 |
| Medical device revenues | 3,891 | ||
| Other revenue | 88 | 9 | 35 |
| Total revenues | 8,397 | 255 | 4,222 |
| Operating expenses: | |||
| Fund management and administration | 4,496 | 282 | 4,250 |
| Employee compensation and benefits | 45,000 | 18,720 | 7,222 |
| General and administrative expense | 19,035 | 445 | 4,229 |
| Impairment of medical device research and development intangible asset | 14,650 | ||
| Marketing and advertising | 281 | 18 | 231 |
| Depreciation and amortization | 254 | 12 | 149 |
| Total operating expenses | 83,716 | 19,477 | 16,081 |
| Investment gains (losses): | |||
| Net unrealized gain (loss) on digital assets, at fair value | 9,888 | -10,133 | |
| Net unrealized gain on investments in preferred equity, at fair value | 3,361 | ||
| Other investment loss | -1,304 | ||
| Other derivative loss | -14,731 | ||
| Total investment gains (losses) | 11,945 | -24,864 | |
| Net operating loss | -63,374 | -44,086 | -11,859 |
| Other income (expense): | |||
| Other income | 2,489 | 68 | 586 |
| Interest expense on long-term notes payable, at fair value | -282 | ||
| Change in fair value on long-term notes payable, at fair value | -2,464 | ||
| Loss on extinguishment of debt | -8,431 | ||
| Loss on change in fair value of bitcoin held as collateral under Coinbase Loan | -2,594 | ||
| Goodwill and intangible asset impairment | -140,785 | ||
| Transaction costs | -6,525 | -7,484 | -15,717 |
| Bargain purchase gain | 66,704 | ||
| Total other income (expense) | 48,897 | -148,201 | -15,131 |
| Net loss before income taxes | -14,477 | -192,287 | -26,990 |
| Net loss | -14,477 | -192,287 | -26,990 |
| Dividends on preferred stock | -73,894 | ||
| Net loss attributable to common stockholders | -88,371 | -192,287 | -26,990 |
| Weighted average number of common shares outstanding: | |||
| Basic (1) | 75,429,254 | 43,617,459 | 2,299,243 |
| Diluted (1) | 75,429,254 | 43,617,459 | 2,299,243 |
| Net loss per common share: | |||
| Basic (1) | -1.17 | -4.41 | -11.74 |
| Diluted (1) | -1.17 | -4.41 | -11.74 |
Income Statement
than share and per share information):
| Successor – Three Months Ended September 30, 2026 | Successor – Nine Months Ended September 30, 2026 | Successor – Period From September 12, 2025 to September 30, 2025 | Predecessor – Period From July 1, 2025 to September 11, 2025 | Predecessor – Period From January 1, 2025 to September 11, 2025 | |
|---|---|---|---|---|---|
| Net income (loss) | 509,032 | -192,287 | -14,366 | ||
| Share-based compensation expense | 6,523 | 16,294 |
Balance Sheet
September 30, 2026 — (in thousands, except share and per share data)
| September 30, 2026 – (unaudited) | December 31, 2025 – (audited) | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 285,405 | 67,499 |
| Investments in preferred equity, at fair value | 50,172 | |
| Prepaid expenses | 1,034 | 2,708 |
| Other current assets | 2,072 | 1,569 |
| Total current assets | 338,683 | 71,776 |
| Digital assets, at fair value | 2,340,192 | 668,486 |
| Property and equipment, net | 731 | 778 |
| Intangible assets, net | 321 | 355 |
| Right-of-use lease assets | 3,717 | 4,037 |
| Other non-current assets | 526 | 95 |
| Total assets | 2,684,170 | 745,527 |
| Current liabilities: | ||
| Compensation and benefits payable | 12,924 | 164 |
| Accounts payable and other liabilities | 7,356 | 8,560 |
| Dividends payable | 14,022 | 2,053 |
| Total current liabilities | 34,302 | 10,777 |
| Operating lease liabilities | 3,218 | 3,512 |
| Total liabilities | 37,520 | 14,289 |
| Mezzanine equity: | ||
| Variable Rate Series A Preferred Stock, $0.001 par value; 40,000,000 and 20,000,000 shares authorized, 12,940,621 and 2,012,729 shares issued and outstanding, $1.3 billion and $201.3 million liquidation preference as of September 30, 2026 and December 31, 2025, respectively | 1,210,820 | 148,802 |
| Total mezzanine equity | 1,210,820 | 148,802 |
| Stockholders’ equity: | ||
| Class A common stock, $0.001 par value; 22,200,000,000 shares authorized, 88,814,706 and 34,936,745 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 89 | 699 |
| Class B common stock, $0.001 par value; 1,050,000,000 shares authorized, 9,198,036 and 9,776,540 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 9 | 196 |
| Additional paid-in capital | 1,998,157 | 1,055,595 |
| Accumulated deficit | -562,425 | -474,054 |
| Total stockholders’ equity | 1,435,830 | 582,436 |
| Total liabilities, mezzanine equity, and stockholders' equity | 2,684,170 | 745,527 |
Cash Flow
From the 10-Q · (in thousands)
| Successor – Nine Months Ended September 30, 2026 – (unaudited) | Successor – Period From September 12, 2025 to September 30, 2025 – (unaudited) | Predecessor – Period From January 1, 2025 to September 11, 2025 – (audited) | |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net loss | -14,477 | -192,287 | -26,990 |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 254 | 12 | 149 |
| Accretion of discount on investments, net | 155 | ||
| Reduction of right-of-use lease assets and operating lease liabilities | 40 | 5 | 91 |
| Net unrealized gain (loss) on digital assets, at fair value | -9,888 | 10,133 | |
| Other investment loss | 1,304 | ||
| Other derivative loss | 14,731 | ||